Roseola infantum is a generally benign, self-limited febrile exanthem of infancy caused by human herpesvirus 6B (HHV-6B, ~90% of cases) or HHV-7, characterized by 3–5 days of high fever followed by a maculopapular rash upon defervescence. [1-2] It accounts for approximately 10% of ED visits for acute febrile illness in children under 2 years and 20% of such visits in those aged 6–12 months. [3] Over 95% of children are seropositive by age 2. [1][4]
1. History
- Fever onset and duration: Abrupt high fever (mean 39.4–39.7°C), lasting 3–5 days (mean 4.1 days) [2-3]
- Rash timing: Maculopapular rash appearing as fever resolves — this temporal relationship is the hallmark; rash lasts ~3–4 days [2]
- Rash distribution: Face and trunk predominantly; blanching, non-pruritic, pink macules/papules [1][5]
- Associated symptoms: Irritability (often prominent), mild diarrhea (68%), cough (50%), decreased oral intake [2]
- Important negatives: No conjunctivitis (unlike measles/Kawasaki), no vesicles, no petechiae/purpura, no joint involvement, no "slapped cheek" appearance
2. Alarm Features
- Seizures — febrile seizures occur in ~8–13% of primary HHV-6 infections; HHV-6 accounts for one-third of febrile seizures in children ≤2 years [2-3]
- Prolonged or focal seizures — HHV-6B is associated with febrile status epilepticus [6-7]
- Encephalitis/encephalopathy — rare but serious; presents with altered consciousness, focal neurologic deficits; all CNS complications occur during the pre-eruptive (febrile) stage [8]
- Bulging anterior fontanelle — occurs in ~26% of confirmed cases; usually benign but warrants evaluation to exclude meningitis [2][9]
- Toxic appearance or hemodynamic instability — should prompt evaluation for sepsis/bacterial superinfection
- Immunocompromised host — HHV-6 reactivation can cause severe systemic disease including encephalitis, hepatitis, and bone marrow suppression [1][10]
3. Medications
- Antipyretics: Acetaminophen (15 mg/kg q4h, max 5 doses/day) or ibuprofen (10 mg/kg q6h, for infants ≥6 months) for comfort; goal is comfort, not normothermia [11]
- Aspirin: Avoid in children due to risk of Reye syndrome [12]
- Antivirals: Not indicated for immunocompetent children. HHV-6 is resistant to acyclovir. Ganciclovir and foscarnet have in vitro activity but are reserved for severe disease in immunocompromised patients (e.g., post-transplant encephalitis) [13-15]
- Antibiotics: Not indicated unless bacterial superinfection is suspected; however, many children receive empiric antibiotics during the pre-eruptive febrile phase before the diagnosis becomes apparent [3]
- Benzodiazepines: For seizures lasting >5 minutes (midazolam, diazepam per febrile seizure protocols) [16]
4. Diet
- Encourage frequent small volumes of clear fluids to prevent dehydration during the febrile phase
- Breast milk or formula should continue as tolerated
- Mild diarrhea is common (68%); oral rehydration solution if needed [2]
- No specific dietary restrictions or triggers
5. Review of Systems
- Neuro: Seizure activity, altered mental status, irritability, lethargy, bulging fontanelle
- GI: Diarrhea, vomiting, poor feeding
- HEENT: Eyelid edema (30%), pharyngeal erythema/papules (65%), inflamed tympanic membranes [2-3]
- Respiratory: Cough (50%), upper respiratory symptoms (41%); lower respiratory findings are uncommon [2-3]
- Lymphatic: Cervical lymphadenopathy (31%) [2]
- Skin: Rash characteristics — timing relative to fever, distribution, blanching, pruritus (typically absent)
6. Collateral History and Family History
- Daycare/sick contacts: HHV-6 is transmitted via saliva; exposure to other febrile children is common
- Family history of febrile seizures: Increases risk of febrile seizures in the child [16]
- Immunocompromised household members or patient: Changes the risk profile significantly [1][10]
- Vaccination history: Recent immunizations may cause fever/rash and should be considered in the differential
7. Risk Factors
- Age 6–15 months — peak incidence; corresponds to waning of maternal antibodies [2-3][17]
- Daycare attendance — increased exposure to respiratory secretions
- No seasonal predilection — occurs year-round [2]
- Family history of febrile seizures — increases seizure risk [16]
- Immunocompromised state — risk of severe/disseminated disease and reactivation [1][10]
8. Differential Diagnosis
The differential is most relevant during the pre-eruptive febrile phase (before the rash clarifies the diagnosis):
- Kawasaki disease — prolonged fever >5 days, conjunctival injection, mucositis, extremity changes, lymphadenopathy; cannot-miss diagnosis [18-19]
- Measles — cough, coryza, conjunctivitis, Koplik spots; rash starts on face and spreads cephalocaudally while fever persists [19-20]
- Scarlet fever — sandpaper rash, pharyngitis, strawberry tongue; rash concurrent with fever [5]
- Erythema infectiosum (fifth disease) — "slapped cheek" rash, low-grade fever, lacy reticular rash on extremities [5]
- Drug eruption — temporal relationship to medication; can mimic viral exanthem, especially with concurrent antibiotic use [21]
- Enteroviral exanthem — hand-foot-mouth disease, herpangina; oral vesicles/ulcers [18][22]
- Urticaria — most common cause of pediatric exanthem in the ED; wheals, pruritus, blanching [18]
- Bacterial sepsis/meningitis — must be excluded in ill-appearing febrile infants, especially <60 days [23]
- UTI — common occult source of fever in this age group
The following figure provides a diagnostic algorithm for childhood rashes:
9. Past Medical History
- Prior febrile seizures (recurrence risk ~30%)
- Prematurity or neonatal complications
- Known immunodeficiency or immunosuppressive therapy
- History of transplantation (risk of HHV-6 reactivation)
- Prior episodes of roseola (second episodes can occur, typically from HHV-7 after initial HHV-6B infection) [1]
10. Physical Exam
- Vitals: High fever (often 39–40.5°C) during pre-eruptive phase; tachycardia proportional to fever
- General: Irritability is common; may appear "sicker" than other febrile illnesses during the febrile phase [3]
- Skin: Blanching, pink, macular or maculopapular rash on trunk and face; non-tender, non-pruritic; appears as fever breaks [2][5]
- HEENT: Periorbital/eyelid edema (30%), erythematous pharyngeal papules (Nagayama spots, 65%), inflamed tympanic membranes [2-3][25]
- Fontanelle: Bulging in ~26% — does not necessarily indicate meningitis in the context of roseola, but warrants clinical judgment [2][9]
- Lymph nodes: Mild cervical lymphadenopathy (31%) [2]
- Neuro: Assess for meningismus, focal deficits, altered consciousness
11. Lab Studies
- Routine labs are generally unnecessary in well-appearing children with classic presentation
- CBC (if obtained): Expect leukopenia (mean WBC 8,900/mm³), lymphopenia, and neutropenia — this pattern is characteristic and distinguishes HHV-6 from bacterial infection [3][26]
- CRP/procalcitonin: May be mildly elevated; useful to risk-stratify if bacterial infection is a concern
- Urinalysis: Should be obtained in febrile infants <24 months without a clear source per AAP guidelines [23]
- Blood culture: Consider in ill-appearing or young febrile infants during the pre-eruptive phase
- HHV-6 PCR (blood): Not routinely needed; useful in immunocompromised patients or atypical/severe presentations [1][27]
- LFTs: Consider if hepatitis suspected (rare complication) [25]
- CSF: Only if meningitis/encephalitis is suspected; CSF is typically acellular in HHV-6 CNS disease [3][8]
12. Imaging
- Not routinely indicated for classic roseola
- CT head: Consider if encephalitis/encephalopathy suspected (focal deficits, prolonged altered mental status); may show abnormalities in encephalitis cases [8]
- MRI brain: Gold standard for HHV-6 encephalitis (mesial temporal lobe involvement in post-transplant setting)
- Chest X-ray: Only if lower respiratory symptoms are prominent (uncommon in roseola) [3]
13. Special Tests
- HHV-6 serology: IgM/IgG — useful for retrospective confirmation; not practical in the acute ED setting [1]
- HHV-6 PCR: Blood or CSF — most useful in immunocompromised patients or CNS complications [10][27]
- Lumbar puncture: If meningitis/encephalitis is suspected; send for cell count, glucose, protein, Gram stain, culture, and viral PCR [8]
- EEG: If encephalopathy or seizures with atypical features [8]
14. ECG
- Not routinely indicated
- Consider if myocarditis is suspected (rare complication) — look for ST changes, arrhythmias, low voltage
- Myocarditis has been reported in rare case reports of HHV-6 infection
15. Assessment
Roseola infantum is a clinical diagnosis made retrospectively when the characteristic rash appears upon defervescence in a child aged 6–15 months. [1][5] The major clinical challenge occurs during the pre-eruptive febrile phase, when the child presents with high fever and nonspecific symptoms, often prompting evaluation for occult bacteremia or sepsis. In the landmark NEJM prospective study, the most common ED diagnoses assigned to children with primary HHV-6 infection were "fever with otitis" (30%) and "fever of undetermined cause/possible sepsis" (29%). [3]
Severity stratification
- Typical/mild: High fever → rash on defervescence → resolution within days
- Moderate: Febrile seizure (simple) — common, generally benign prognosis [16]
- Severe: Encephalitis/encephalopathy, febrile status epilepticus, disseminated disease in immunocompromised — rare but potentially fatal [7-8]
16. Treatment Plan
Initial stabilization
- ABCs if seizure; benzodiazepine for seizures >5 minutes [16]
- IV access and fluid resuscitation if dehydrated or ill-appearing
Supportive care (mainstay)
- Acetaminophen or ibuprofen for fever-related discomfort [11]
- Oral hydration; small frequent feeds
- The rash requires no treatment and is not contagious at the time of appearance [1]
Antivirals
- Not indicated in immunocompetent children [1][13]
- In immunocompromised patients with severe HHV-6 disease: ganciclovir or foscarnet (acyclovir is ineffective against HHV-6) [13-15]
Febrile seizure management
- Simple febrile seizures: Reassurance; no antiepileptic prophylaxis indicated [16]
- Antipyretics do not prevent febrile seizures [16]
- Complex or prolonged seizures: Neuroimaging and further workup as indicated [8]
17. Disposition
Discharge criteria (majority of cases)
- Well-appearing child with classic presentation (fever → rash)
- Tolerating oral fluids
- No seizures or single simple febrile seizure with return to baseline
- Reliable caregiver with return precautions
Admission criteria
- Ill or toxic appearance
- Febrile status epilepticus or complex/focal seizures [6][8]
- Signs of encephalitis/encephalopathy (altered mental status, focal deficits)
- Inability to maintain hydration
- Immunocompromised patient with suspected HHV-6 disease
- Young febrile infant (<60 days) requiring sepsis workup per AAP guidelines [23]
Specialist consultation triggers
- Pediatric neurology: Encephalitis, status epilepticus, focal seizures
- Pediatric infectious disease: Immunocompromised host, atypical or severe course
- Pediatric ICU: Hemodynamic instability, refractory seizures
18. Follow Up / Return Precautions
Follow-up timing
- Routine PCP follow-up within 1–2 days if discharged during the febrile phase before rash appears
- No follow-up needed for resolved, classic roseola unless complications occurred
Return precautions — instruct caregivers to return for
- Seizure activity
- Lethargy, poor responsiveness, or altered behavior
- Inability to keep fluids down or signs of dehydration (no tears, decreased urine output)
- Fever persisting >5–6 days or recurrence of fever after defervescence
- Petechial or purpuric rash (non-blanching)
- Bulging fontanelle with irritability
Counseling points
- Roseola is self-limited; the rash itself is a sign of recovery, not worsening [1]
- The child is most contagious during the febrile phase before the rash appears
- Antipyretics improve comfort but do not prevent febrile seizures [11][16]
- Expected recovery: Complete resolution within 7–10 days with no long-term sequelae in immunocompetent children [1-2]
References
1. Roseola Infantum and Its Causal Human Herpesviruses. — Stone RC, Micali GA, Schwartz RA. International Journal of Dermatology. 2014.
2. Clinical Features of Infants With Primary Human Herpesvirus 6 Infection (Exanthem Subitum, Roseola Infantum). — Asano Y, Yoshikawa T, Suga S, et al. Pediatrics. 1994.
3. Human Herpesvirus-6 Infection in Children -- A Prospective Study of Complications and Reactivation. — Hall CB, Long CE, Schnabel KC, et al. The New England Journal of Medicine. 1994.
4. Frequency evaluation and molecular characterization of HHV‐6 and HHV‐7 among children under 5 years with fever and skin rash. — Keshavarz M, Ghasemi S, Arjeini Y, et al. Journal of Medical Virology. 2023.
5. Common Skin Rashes in Children. — Allmon A, Deane K, Martin KL. American Family Physician. 2015.
6. Children infected by human herpesvirus 6B with febrile seizures are more likely to develop febrile status epilepticus: A case‐control study in a referral hospital in Zambia. — Tembo J, Chandwe K, Kabwe M, et al. Journal of Medical Virology. 2018.
7. Clinical Impact of Primary Infection With Roseoloviruses. — Tesini BL, Epstein LG, Caserta MT. Current Opinion in Virology. 2014.
8. Clinical and Virological Analyses of 21 Infants With Exanthem Subitum (Roseola Infantum) and Central Nervous System Complications. — Suga S, Yoshikawa T, Asano Y, et al. Annals of Neurology. 1993.
9. The Not-So-Soft Spot: Pathophysiology of the Bulging Fontanelle in Association With Roseola. — Cristoforo T, Le NK, Rye-Buckingham S, Hudson WB, Carroll LF. Pediatric Emergency Care. 2020.
10. Human Herpesviruses 6A, 6B, and 7. — Agut H, Bonnafous P, Gautheret-Dejean A. Microbiology Spectrum. 2016.
11. Fever and Antipyretic Use in Children. — Sullivan JE, Farrar HC. Pediatrics. 2011.
12. Treatment of Fever in Childhood. — Adam D, Stankov G. European Journal of Pediatrics. 1994.
13. Summary of the 11th International Conference on Human Herpesviruses‐6A, ‐6B, and ‐7. — Komaroff AL, Zerr DM, Flamand L. Journal of Medical Virology. 2020.
14. Susceptibility of Human Herpesvirus 6 to Antivirals in Vitro. — Burns WH, Sandford GR. The Journal of Infectious Diseases. 1990.
15. Chromosomally integrated human herpesvirus 6: questions and answers. — Pellett PE, Ablashi DV, Ambros PF, et al. Reviews in Medical Virology. 2012.
16. Febrile Seizures: Risks, Evaluation, and Prognosis. — Smith DK, Sadler KP, Benedum M. American Family Physician. 2019.
17. Non‐A to E hepatitis in children: Detecting a novel viral epidemic during the COVID ‐19 pandemic. — Brüssow H. Microbial Biotechnology. 2023.
18. Clinical and Laboratory Diagnosis of Exanthems Among Japanese Children Younger Than 6 Years Old in the Post-Measles-Rubella Vaccine Era. — Yasuda M, Shoji K, Tomita K, et al. The Pediatric Infectious Disease Journal. 2024.
19. The Rash With Maculopapules and Fever in Children. — Muzumdar S, Rothe MJ, Grant-Kels JM. Clinics in Dermatology. 2019.
20. Rubella. — Banatvala JE, Brown DW. Lancet. 2004.
21. Skin Eruptions in Children: Drug Hypersensitivity vs Viral Exanthema. — Tsabouri S, Atanaskovic-Markovic M. Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology. 2021.
22. Clinical Features, Diagnosis, and Management of Enterovirus 71. — Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. The Lancet. Neurology. 2010.
23. Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old. — Pantell RH, Roberts KB, Adams WG, et al. Pediatrics. 2021.
24. Other Childhood Rashes. — Gary Foley Clinical Guide to Paediatrics. 2022.
25. A 1-Year-Old Boy Presenting With Roseola Accompanied by Bilateral Eyelid Oedema and Acute Infectious Mononucleosis Syndrome Caused by Human Herpesuvirus-6b: A Case Report. — Mizuno S, Horiba K, Nakahashi T, et al. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases. 2025.
26. Roseola Infantum During the COVID-19 Pandemic. — Aktürk H, Bağci MS, Yiğit MH, et al. Journal of Pediatric Hematology/Oncology. 2022.
27. Human Herpesvirus-6 and -7 Infections in Children: Agents of Roseola and Other Syndromes. — Leach CT. Current Opinion in Pediatrics. 2000.